Picture 1 of 1
Gallery
Picture 1 of 1
Have one to sell?
Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials,...
by Teicher, Beverly A. | HC | VeryGood
US $8.11
ApproximatelyRM 34.33
Condition:
“May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend ”... Read moreabout condition
Very Good
A book that has been read but is in excellent condition. No obvious damage to the cover, with the dust jacket included for hard covers. No missing or damaged pages, no creases or tears, and no underlining/highlighting of text or writing in the margins. May be very minimal identifying marks on the inside cover. Very minimal wear and tear.
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Shipping:
Free USPS Media MailTM.
Located in: Aurora, Illinois, United States
Delivery:
Estimated between Sat, 26 Jul and Thu, 31 Jul
Returns:
30 days return. Seller pays for return shipping.
Coverage:
Read item description or contact seller for details. See all detailsSee all details on coverage
(Not eligible for eBay purchase protection programmes)
Seller assumes all responsibility for this listing.
eBay item number:376364775524
Item specifics
- Condition
- Very Good
- Seller Notes
- Binding
- Hardcover
- Book Title
- Anticancer Drug Development Guide
- Weight
- 2 lbs
- Product Group
- Book
- IsTextBook
- Yes
- ISBN
- 9781588292285
About this product
Product Identifiers
Publisher
Humana Press
ISBN-10
1588292282
ISBN-13
9781588292285
eBay Product ID (ePID)
6036695
Product Key Features
Number of Pages
Xiv, 451 Pages
Language
English
Publication Name
Anticancer Drug Development Guide : Preclinical Screening, Clinical Trials, and Approval
Subject
Oncology, Pharmacology
Publication Year
2004
Type
Textbook
Subject Area
Medical
Series
Cancer Drug Discovery and Development Ser.
Format
Hardcover
Dimensions
Item Weight
79.7 Oz
Item Length
10 in
Item Width
7 in
Additional Product Features
Edition Number
2
Intended Audience
Scholarly & Professional
LCCN
2003-024925
Reviews
From Reviews of the First Edition: "...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'." -Unlisted Drugs "...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology, From Reviews of the First Edition:"...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'." -Unlisted Drugs"...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology
Dewey Edition
22
Number of Volumes
1 vol.
Illustrated
Yes
Dewey Decimal
616.99/4061
Table Of Content
I: In Vitro Methods.- 1 High-Volume Screening.- 2 High-Throughput Screening in Industry.- 3 The NCI Human Tumor Cell Line (60-Cell) Screen: Concept, Implementation, and Applications.- 4 Human Tumor Screening.- II: In Vivo Methods.- 5 Murine L1210 and P388 Leukemias.- 6 In Vivo Methods for Screening and Preclinical Testing: Use of Rodent Solid Tumors for Drug Discovery.- 7 Human Tumor Xenograft Models in NCI Drug Development.- 8 NCI Specialized Procedures in Preclinical Drug Evaluations.- 9 Patient-Like Orthotopic Metastatic Models of Human Cancer.- 10 Preclinical Models for Combination Therapy.- 11 Models for Biomarkers and Minimal Residual Tumor.- 12 Spontaneously Occurring Tumors in Companion Animals As Models for Drug Development.- III: Nonclinical Testing to Support Human Trials.- 13 Nonclinical Testing: From Theory to Practice.- 14 Nonclinical Testing for Oncology Drug Products.- 15 Nonclinical Testing for Oncology Biologic Products.- IV: Clinical Testing.- 16 Working With the National Cancer Institute.- 17 Phase I Trial Design and Methodology for Anticancer Drugs.- 18 Phase II Trials: Conventional Design and Novel Strategies in the Era of Targeted Therapies.- 19 Drug Development in Europe: The Academic Perspective.- 20 The Phase III Clinical Cancer Trial.- 21 Assessing Tumor-Related Symptoms and Health-Related Quality of Life in Cancer Clinical Trials: A Regulatory Perspective.- 22 The Role of the Oncology Drug Advisory Committee in the FDA Review Process for Oncologic Products.- 23 FDA Role in Cancer Drug Development and Requirements for Approval.
Synopsis
Focuses on both in vitro and in vivo screening methods; reviews how to work with the NCI, EORTC, and FDA requirements for approval; details successful strategies for working through phase I, II, and III clinical trials; in vivo methods include murine L1210 and P388 leukemias, high dose models, and human tumor xenografts; in vitro methods include high volume screening and human tumor screening., This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
LC Classification Number
RC254-282
Item description from the seller
Seller feedback (5,686,712)
- h***l (573)- Feedback left by buyer.Past monthVerified purchaseAdvert8sed as Autographed by Author and did not gave his signature. ebay refunded my money to me promptly.
- f***f (4324)- Feedback left by buyer.Past monthVerified purchaseItem exactly as described and promptly shipped
- 1***m (1601)- Feedback left by buyer.Past monthVerified purchaseAs described. Good transaction.
More to explore :
- Nonfiction Books in English Fiction & Drugs,
- Nonfiction Drugs Fiction & Nonfiction Books,
- Development Studies Textbooks,
- Nonfiction Books Fiction & Personal Development,
- Development Studies Textbooks in English,
- TV Guide Magazines,
- Science Study Guides & Test Prep,
- Insight Guides Nonfiction Books Fiction & Travel Guide,
- Christianity Study Guides & Test Prep,
- Biology Study Guides & Test Prep
Seller feedback (5,686,712)
- h***l (573)- Feedback left by buyer.Past monthVerified purchaseAdvert8sed as Autographed by Author and did not gave his signature. ebay refunded my money to me promptly.
- f***f (4324)- Feedback left by buyer.Past monthVerified purchaseItem exactly as described and promptly shipped
- 1***m (1601)- Feedback left by buyer.Past monthVerified purchaseAs described. Good transaction.